Akzo Nobel Settles Antitrust Litigation Over Remeron Patents For $59.8M

Law360, New York (October 2, 2004, 12:00 AM EDT) -- Dutch conglomerate Akzo Nobel and its subsidiary Organon USA have agreed to settle litigation over its patents for antidepressant Remeron for $59.8 million, but the company still faces risks of class-action complaints.

The lawsuit alleged that Akzo’s assertion of the patent delayed the market introduction of mirtazapine, the generic name of the drug, and violated antitrust laws.

The settlement resolves direct claims brought by nine large chainstore and grocery store pharmacies, including Wal-Mart, and indirect claims brought by attorney general offices and third parties.

Akzo may...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.